PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, Division of Respirology, McGill University Health Centre, Montreal, Quebec, Canada nicole.ezer@mcgill.ca.\', \'Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.\', \'Division of Infectious Diseases, University of British Columbia, Vancouver, British Columbia, Canada.\', \'Department of Medicine, Division of Infectious Diseases, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.\', \'Department of Medicine, Division of Respirology, McGill University Health Centre, Montreal, Quebec, Canada.\', \'Clinical Practice Assessment Unit, Department of Medicine, Montreal, Quebec, Canada.\', \'Department of Medicine, Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.\', \'Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montreal, Quebec, Canada.\', \'Department of Medicine, Division of General Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1136/bmj-2021-068060
?:hasPublicationType
?:journal
  • BMJ (Clinical research ed.)
is ?:pmid of
?:pmid
?:pmid
  • 34728476
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all